TNF-Alpha Inhibitor Compounds for Severe Autoimmune Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aberrant TNFα signaling contributes to inflammatory conditions and autoimmune diseases, such as rheumatoid arthritis, for which effective therapeutic interventions are lacking.
Innovation Solution
Development of compounds of Formula (I) or their pharmaceutically acceptable salts, solvates, deuteroisotopes, or N-oxides, which act as inhibitors of TNFα signaling, formulated into pharmaceutical compositions for targeted treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional TNFα inhibitors are used, then inflammatory conditions can be treated, but therapeutic efficacy is insufficient for severe autoimmune diseases
Solution Approach 1:
The patent modifies the chemical structure of TNFα inhibitors by changing molecular parameters such as introducing deuterium atoms, altering substituent groups (R1-R14), and modifying the core heterocyclic ring system. These parameter changes create a series of analogs with progressively improved binding affinity and biological activity, resolving the contradiction between therapeutic efficacy and treatment coverage by providing optimized compounds that maintain reliability while expanding adaptability to severe autoimmune conditions
2Reliability
If new TNFα inhibitor compounds are developed, then therapeutic efficacy is improved, but development complexity increases
Solution Approach 1:
The patent segments the TNFα inhibitor molecule into distinct functional modules: a core heterocyclic ring system (Ring A with W, X, Y, Z positions), substituent groups (R1-R14), and optional deuterium labeling. This segmentation allows systematic optimization of each module independently while maintaining overall molecular integrity, thereby improving therapeutic efficacy without unmanageably increasing development complexity
Solution Approach 2:
The patent employs systematic parameter changes by varying substituent groups (R1-R14) and heterocyclic ring configurations in a controlled manner. Each parameter modification is designed to enhance specific biological properties while maintaining synthetic feasibility, resolving the contradiction between improved efficacy and manageable complexity through structured molecular design
Data Source
AI summary
Provided herein are inhibitors of TNF-alpha, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNF-alpha inhibitory compounds for the treatment of diseases or disorders.